Tobamovirus-based virus-like particles and vaccines

Patent metadata

Field	Value
Publication number	US-11285204-B2
Application number	US-201816649567-A
Country	US
Kind code	B2
Filing date	Sep 21, 2018
Priority date	Sep 22, 2017
Publication date	Mar 29, 2022
Grant date	Mar 29, 2022

Abstract

The disclosure generally provides recombinant proteins comprising Tobamovirus capsid proteins and an immunogenic epitope of an antigen of interest. The recombinant protein can be used to assemble an array comprising a plurality of associated recombinant proteins that can enhance the immunogenicity of the epitope and induce and/or enhance an immune response to the antigen. The disclosure also provides compositions, such as vaccines, that include the recombinant protein as well as methods for inducing and/or enhancing an immune response in a mammal.

First claim

We claim:

1. A recombinant protein comprising a modified Tobamovirus capsid protein and an immunogenic epitope of an antigen of interest, wherein the modified Tobamovirus capsid protein comprises an amino acid sequence selected from the group consisting of: amino acid residues 8-148 of SEQ ID NO: 2, amino acid residues 8-141 of SEQ ID NO: 4, amino acid residues 8-146 of SEQ ID NO: 21, and amino acid residues 8-148 of SEQ ID NO: 22, and wherein:
when the modified Tobamovirus capsid protein comprises SEQ ID NO: 2, the immunogenic epitope replaces amino acid residues 51-57 of SEQ ID NO: 2;
when the modified Tobamovirus capsid protein comprises SEQ ID NO: 4, the immunogenic epitope replaces amino acid residues 50-51 of SEQ ID NO: 4;
when the modified Tobamovirus capsid protein comprises SEQ ID NO: 21, the immunogenic epitope is inserted at amino acid residue 53 of SEQ ID NO: 21; and when the modified Tobamovirus capsid protein comprises SEQ ID NO: 22, the immunogenic epitope is inserted at amino acid residue 53 of SEQ ID NO: 22.

2. The recombinant protein of claim 1 , wherein the immunogenic epitope is derived from an antigen that induces an immune response against cancer cells; an antigen that induces an immune response against an infectious disease; or an antigen that induces an immune response against allergens.

3. The recombinant protein of claim 1 , wherein the immunogenic epitope is derived from a virus or bacterium.

4. The recombinant protein of claim 1 , wherein the immunogenic epitope is derived from a Plasmodium species.

5. The recombinant protein of claim 1 , selected from the group consisting of: SEQ ID NO: 5; SEQ ID NO: 6; SEQ ID NO: 7; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18; SEQ ID NO: 19; SEQ ID NO: 20; SEQ ID NO: 23; SEQ ID NO: 24; and SEQ ID NO: 25.

6. A composition comprising the recombinant protein of claim 1 , selected from the group consisting of: SEQ ID NO: 5; SEQ ID NO: 6, SEQ ID NO: 7; SEQ ID NO: 10; SEQ ID NO: 11; SEQ ID NO: 12; SEQ ID NO: 14; SEQ ID NO: 15; SEQ ID NO: 16; SEQ ID NO: 17; SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20; SEQ ID NO: 23; SEQ ID NO: 24; and SEQ ID NO: 25.

7. A vaccine comprising the recombinant protein of claim 1 .

8. The vaccine of claim 7 further comprising an adjuvant.

9. The vaccine of claim 7 , wherein the vaccine comprises a plurality of the recombinant proteins that assemble in an array that forms an interior region and an external region, wherein the immunogenic epitope is displayed on the external region of the array.

10. The vaccine of claim 9 , wherein the immunogenic epitope comprises the amino acid sequence (NPNA)n of circumsporozoite protein (CSP) from P. falciparum , wherein n is an integer selected from 1 to 20.

11. The vaccine of claim 10 , wherein n is an integer selected from 1-10.

12. The vaccine of claim 10 , wherein n is 5.

13. A method for purifying the recombinant protein of claim 1 , the method comprising: expressing the recombinant protein in a host cell; and isolating the recombinant protein.

14. A method of enhancing immunogenicity of an amino acid antigen, wherein the method comprises:
expressing a recombinant protein that comprises the amino acid antigen and a modified Tobamovirus capsid protein;
isolating the recombinant protein under conditions that allow the recombinant protein to assemble in an array of monomers that forms an interior region and an external region, wherein the amino acid antigen is displayed on the external region of the array of monomers, and wherein the modified Tobamovirus capsid protein comprises an amino acid sequence selected from the group consisting of: amino acid residues 8-148 of SEQ ID NO: 2, amino acid residues 8-141 of SEQ ID NO: 4, amino acid residues 8-146 of SEQ ID NO: 21, and amino acid residues 8-148 of SEQ ID NO: 22, and wherein:
when the modified Tobamovirus capsid protein comprises SEQ ID NO: 2, the amino acid antigen replaces amino acid residues 51-57 of SEQ ID NO: 2;
when the modified Tobamovirus capsid protein comprises SEQ ID NO: 4, the amino acid antigen replaces amino acid residues 50-51 of SEQ ID NO: 4;
when the modified Tobamovirus capsid protein comprises SEQ ID NO: 21, the amino acid antigen is inserted at amino acid residue 53 of SEQ ID NO: 21; and
when the modified Tobamovirus capsid protein comprises SEQ ID NO: 22, the amino acid antigen is inserted at amino acid residue 53 of SEQ ID NO: 22.

15. The method of claim 14 , wherein the modified Tobamovirus capsid protein is selected from the group consisting of a modified Tobacco mosaic virus (TMV) capsid protein and a modified zucchini green mottled mosaic virus (ZMV) capsid protein.

16. A method of inducing an immune response in a mammal comprising:
administering to the mammal an effective amount of the composition of claim 6 , to induce an immune response in the mammal.

17. The recombinant protein of claim 1 , further comprising a N-terminal histidine tag.

18. The recombinant protein of claim 4 , wherein the immunogenic epitope comprises the amino acid sequence (NPNA)n of circumsporozoite protein (CSP) from P. falciparum , wherein n is an integer selected from 1 to 20.

19. The vaccine of claim 10 , wherein the vaccine comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 19, and SEQ ID NO: 20.

20. The method of claim 13 , wherein the host cell is E. coli.

Assignees

• Government Of The United States As Represented By The Secretary Of The Army
• The Government Of The United States As Represen

Inventors

• Dutta Sheetij
• Batchelor Adrian
• Khan Farhat
• Langowski Mark

Classifications

• A61K2039/6075

  Viral proteins · CPC title

• A61K2039/64

  characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units · CPC title

• C07K14/08 Primary

  RNA viruses · CPC title

• A61K2039/5258

  Virus-like particles · CPC title

• C12N2770/00034

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title